Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Our choice today is maple bourbon. Meanwhile, we have assembled a new list of items of interest to help you on your journey today. Best of luck and, as always, do keep in touch. …
Biogen (BIIB) is preparing for its largest-ever layoff in which more than 1,000 employees are expected to lose their jobs, STAT reports. Details are still being ironed out, including sign-off from the Biogen board of directors, but the restructuring plan would cut expenses in the range of $500 million to $750 million. People close to Biogen told STAT the company’s top scientist, Al Sandrock, was pushed out, and Alphonse Galdes, a company lifer who oversees global manufacturing and who has been a stabilizing force in its managerial ranks for nearly three decades, is also leaving the company. The moves come after the polarizing approval and disastrous commercial rollout of the Aduhelm drug for Alzheimer’s.
People who received two doses of the Covid-19 vaccine from Pfizer (PFE) and BioNTech (BNTX) are likely susceptible to infection from the Omicron variant of the coronavirus, but a third shot restores antibody activity against the virus, STAT writes. A third dose increased antibodies 25-fold compared with two doses. Still, two doses may prove effective in preventing severe illness from Covid-19, because immune cells are still able to recognize 80% of parts of the spike protein the vaccine targets. The findings suggest two doses may be far less effective against Omicron than earlier virus strains, and a third dose will be needed for a strong immune defense against Omicron.
Create a display name to comment
This name will appear with your comment